PT  - JOURNAL ARTICLE
AU  - Bastiani, Luca
AU  - Fortunato, Loredana
AU  - Pieroni, Stefania
AU  - Bianchi, Fabrizio
AU  - Adorni, Fulvio
AU  - Prinelli, Federica
AU  - Giacomelli, Andrea
AU  - Pagani, Gabriele
AU  - Maggi, Stefania
AU  - Trevisan, Caterina
AU  - Noale, Marianna
AU  - Jesuthasan, Nithiya
AU  - Sojic, Aleksandra
AU  - Pettenati, Carla
AU  - Andreoni, Massimo
AU  - Incalzi, Raffaele Antonelli
AU  - Galli, Massimo
AU  - Molinaro, Sabrina
TI  - EPICOVID19: Psychometric assessment and validation of a short diagnostic scale for a rapid Covid-19 screening based on reported symptoms
AID  - 10.1101/2020.07.22.20159590
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.22.20159590
4099  - http://medrxiv.org/content/early/2020/07/31/2020.07.22.20159590.short
4100  - http://medrxiv.org/content/early/2020/07/31/2020.07.22.20159590.full
AB  - Background Confirmed COVID-19 cases have been registered in more than two hundred countries and regions and of July 28 over 16 million cases of COVID-19, including 650805 deaths, have been reported to WHO. The number of cases changes quickly and varies depending upon which source you use to track, so in the current epidemiological context, the early recognition is critical for the rapid identification of suspected cases (with SARS-CoV-2 infection-like symptoms and signs) to be immediately subjected to quarantine measures. Although surveys are widely used for identifying COVID-19 cases, outcomes and associated risks, no validated epidemiological tool exists for surveying SARS-CoV-2 infection in the population so far.Methods Our study is the phase II of the EPICOVID19 Italian national survey, launched in April 2020 including a national convenience sample of 201121 adults, who voluntarily filled the EPICOVID19 questionnaire. The phase II questionnaire was mailed to all subjects who underwent tests for COVID-19 by nasopharyngeal swab (NPS) and who accepted to be involved in the second phase of the study, focused on the results reported for NPS and/or serological IgG/IgM tests. We evaluated the capability of the self-reported symptoms collected through the EPICOVID19 questionnaire to discriminate the COVID-19 among symptomatic subjects, in order to identify possible cases to undergo instrumental measurements and clinical examinations. We defined a method for the identification of a total score and validated it with reference to the serological and molecular clinical diagnosis, using four standard steps: identification of critical factors, confirmation of presence of latent variable, development of optimal scoring algorithm and validation of the scoring algorithm.Findings 2703 subjects [66% response rate] completed the Phase II questionnaire. Of 2703 individuals, 694 (25.7%) were NPS(+) and of these 84 (12.1% of the 694 NPS(+)) were asymptomatic. In the individuals who performed serological testing, of the 472 who did IgG(+) and 421 who did IgM(+), 22.9% and 11.6% tested positive, respectively. Among IgG(+) 1 of 108 subjects was asymptomatic (0.9%) while 5/49 subjects among IgM(+) were asymptomatic (10.2%). Compared with NPS(-), among NPS(+) subjects there was a higher rate for Fever (421 [60.7%] vs 391[19.5%]; p<0.0001), Loss of Taste and/or Smell (365 [52.6%] vs 239 [11.9%]; p<0.0001) and Cough (352 [50.7%] vs 580 [28.9%]; p<0.0001). Also for other symptoms the frequencies were significantly higher in NPS(+) subjects than in NPS(-) ones (p<0.001). Among groups with serological tests, the symptoms with higher percentages in the subjects IgG(+) were Fever (65 [60.2%] vs 43[11.8%]; p<0.0001) and Pain in muscles, bones, joints (73 [67.6%] vs 71 [19.5%]; p<0.0001). For the COVID-19 self-reported symptoms items, exploratory (proportion variance explained [89.9%]) and confirmatory factor analysis results (SMSR 0.072; RMSEA 0.052) highlights the presence of one latent variable (factor) underlying the symptoms. We define the one-factor solution as EPICOVID19 diagnostic scale and optimal score for each items was identified: Respiratory problems (1.03), Chest pain (1.07), Loss of Taste and/or Smell (0.97) and Tachycardia (palpitations) (1.05) were the most important symptoms.The cut-off score was 2.56 (Sensitivity 76.56%; Specificity 68.24%) in NPS(+) and 2.59 (Se 80.37; Sp 80.17) in IgG(+) subjects.Interpretation We developed a short diagnostic scale to detect subjects with symptoms potentially associated with COVID-19 among a wide population. Early recognition screening and rapid diagnosis are essential to prevent transmission and provide supportive care in a timely manner and our score supports the potential for identifying individuals who need to seek immediate clinical evaluation. Although these results are referred to the Italian pandemic period, this short diagnostic scale could be optimised and tested as a screening tool in other similar pandemic contexts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical statement and consent form EPICOVID19 phase II study was approved by the Ethical Committee of the Istituto Nazionale per le Malattie Infettive I.R.C.C.S. L. Spallanzani as an amendment of the EPICOVID19 epidemiological study (approval No. 93 of the trial register). Data transfer was safeguarded by means of password protection and encrypting/decrypting policy; all data were handled and stored in accordance with the EU GDPR 2016/679 (http://gdpr-info.eu/). Informed consent was accessible on the home page of the platform and participants were asked to review before starting the compilation, thus explaining the purpose of the study and which data were to be collected and how data were stored. Email address is the personal data leaved on a voluntary basis in phase I, and in our study it was only used: 1) to send email invitation to the phase II survey; 2) to link the information related to the results (swabs and/or antibodies IgG, IgM) to the information on symptoms collected during the phase I survey. In the participation mail, the person was able to participate by clicking on the provided link to the survey; to not participate ignoring the invitation; to communicate to a specific address (valid-epicovid19@ifc.cnr.it) the request of deletion of the email address from the database. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll manuscript data are available on request